HSBC Knock-Out LONN/ DE000HS47KY2 /
07.11.2024 12:52:10 | Изменение-0.72 | Бид20:00:00 | Предложение20:00:00 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
18.95EUR | -3.66% | - Величина цены спроса: - |
- Величина цены предложения: - |
LONZA N | 365.5688 CHF | 31.12.2078 | Call |
GlobeNewswire
26.08
Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences
GlobeNewswire
23.08
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire
08.08
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
06.08
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
14.06
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire
30.05
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire
15.05
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire
08.05
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
04.04
Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire
04.04
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...
GlobeNewswire
27.02
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
04.01
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire
19.12.2023
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...
GlobeNewswire
09.12.2023
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...
GlobeNewswire
07.12.2023
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...
GlobeNewswire
06.11.2023
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
16.10.2023
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...
GlobeNewswire
02.10.2023
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
GlobeNewswire
20.09.2023
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница